Showing 1 - 10 of 11 Appel or shroff or greene or thonhoff

Status: Enrolling

Investigator: Jason Thonhoff

Study Coordinator: Aramide Balogun

Phone: 713.441.6937

In Amyotrophic Lateral Sclerosis (ALS), the reduction of regulatory T lymphocyte (Treg) numbers and suppressive function correlates with rapid disease progression. We completed a phase 1 study of infusions of expanded autologous Tregs in combina ... Read more >

Status: Open Not Enrolling

Investigator: Jason Thonhoff

Study Coordinator: Aramide Balogun

Phone: 713.441.6937

The purpose of this study is to measure the safety and effectiveness of Spinraza in adults with SMA. ... Read more >

Status: Enrolling

Investigator: Stanley Appel

Study Coordinator: Aramide Balogun

Phone: 713.441.6937

The purpose of this protocol is to develop and maintain a biospecimen bank comprised of blood, urine, CSF collected during diagnostic evaluations, tissue from biopsies and autopsies collected from patients with neurological disease and non-neu ... Read more >

Status: Enrolling

Investigator: Jason Thonhoff

Study Coordinator: Anjana Singh

Phone: 713.441.9120

This leukapheresis study proposes to continue our work in developing and optimizing our Treg manufacturing process. Under this study, up to 10 patients with ALS will undergo leukapheresis. Their Tregs will subsequently be isolated and expand ... Read more >

Status: Open Not Enrolling

Investigator: Sheetal Shroff

Study Coordinator: Anjana Singh

Phone: 713.441.9120

The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG). ... Read more >

Status: Open Not Enrolling

Investigator: Stanley Appel

Study Coordinator: Aramide Balogun

Phone: 713.441.6937

The purpose of this protocol is to develop and maintain a clinical findings data bank including diagnostic evaluations obtained from medical records sent from prior medical evaluations, diagnostic intake evaluations and follow-up care in the Met ... Read more >

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Aramide Balogun

Phone: 713.441.6937

Provide natural history data, biomarkers, and biological understanding of the phenotypic heterogeneity of myotonic dystrophy type 1 (DM1). ... Read more >

Status: Open Not Enrolling

Investigator: Stanley Appel

Study Coordinator: Sharon Halton

Phone: 713.441.3420

The purpose of the this study to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progre ... Read more >

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Anjana Singh

Phone: 713.441.9120

Complement component 5 (C5) inhibition therapies have been available for patients with generalized Myasthenia Gravis (gMG) in the United States since the introduction of Soliris® in late 2017. Alexion is developing potential new therapies that ... Read more >

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Anjana Singh

Phone: 713.441.9120

The purpose of this protocol is to make available clinical findings, including blood pressure, pulmonary function tests, cardiac function tests, clinical evaluations, cognitive evaluations, performance tests, medications, routine blood work eval ... Read more >

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Anjana Singh

Phone: 713.441.9120

This is a registry of people with neuromuscular diseases. It is the intent to follow patients with ALS and other neuromuscular diseases to determine best practices for care delivery. ... Read more >